CSL Seeks Disruption Of HAE Space With Monthly Prevention Product
Executive Summary
Based on top-line Phase III data for garadacimab, CSL is preparing to submit the Factor XIIa inhibitor for US FDA approval for monthly prophylaxis of hereditary angioedema and expand the firm’s HAE franchise.
You may also be interested in...
BioCryst Says Orladeyo On Slow, Steady Ramp To Blockbuster Sales
Company believes its oral HAE prophylaxis will gradually reach the billion-dollar sales threshold, with about 80% of revenue coming from the US market.
Hereditary Angioedema Market Snapshot: Room For Pills And Injections As Prophylaxis Makes Gains
While many HAE patients converted from injectable prophylaxis to BioCryst’s oral Orladeyo last year, physicians said a promising injectable candidate from Ionis could benefit from varied patient preference.
CSL Makes $11.7bn Move On Vifor Pharma In Renal Disease Push
Confirming rumors of an acquisition, CSL will venture into some new territories as well as boost its renal franchise when it takes over Switzerland’s Vifor Pharma in a deal worth $11.7bn.